Name of this page - this is for HTML5 outline...

In pulmonary arterial hypertension (PAH)...
Could more PAH patients benefit from therapies
targeting the prostacyclin pathway?
Learn more
How could we improve utilization of
this important pathway for PAH patients?
Learn more
Should the decision for long-term PAH treatment
be based on short-term trial results?
Learn more
For PAH patients treated with ERA and PDE5i combination therapies, what are the options to improve long-term outcomes?
Learn more